Eton director plans sale of 50,000 shares

Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Paul W. Maier, identified as a director, plans to sell under Rule 144.

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Paul W. Maier, identified as a director, plans to sell under Rule 144. The notice covers a proposed sale of 50,000 shares of common stock, expected to be sold through Raymond James & Associates, Inc. on or about 08/28/2026. The shares are to be sold for the account of Paul W. Maier and are indicated as relating to stock options.

Key Figures

Shares to be sold: 50,000 shares of common stock Proposed sale date: 08/28/2026 Issuer name: Eton Pharmaceuticals, Inc. +1 more

4 metrics

Shares to be sold 50,000 shares of common stock Proposed Rule 144 sale for the account of Paul W. Maier

Proposed sale date 08/28/2026 Expected date for the Rule 144 sale of 50,000 shares

Issuer name Eton Pharmaceuticals, Inc. Issuer of the common stock subject to the Rule 144 notice

Selling person role Director Paul W. Maier is identified as a director of the issuer

Key Terms

Rule 144, stock options, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock options financial

"Common | 08/28/2026 | stock options | issuer"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

attorney-in-fact regulatory

"as attorney-in-fact for Paul W Maier"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Rule 144 sale is being reported for ETON?

The notice reports a proposed Rule 144 sale of 50,000 shares of Eton Pharmaceuticals, Inc. common stock for the account of director Paul W. Maier, with the sale expected on or about 08/28/2026.

Who is the person for whose account ETON securities will be sold?

The securities are to be sold for the account of Paul W. Maier, identified as a director, with information provided pursuant to Rule 144 requirements for such sales.

What type of security is covered by this ETON Rule 144 notice?

The notice covers common stock of Eton Pharmaceuticals, Inc., associated with stock options as indicated in the securities-to-be-sold section.

Which broker is designated for the planned ETON share sale?

The planned sale of Eton Pharmaceuticals, Inc. shares is listed through Raymond James & Associates, Inc., located at 880 Carillon Parkway, St. Petersburg, Florida.

When are the ETON shares expected to be sold under Rule 144?

The Rule 144 notice indicates an expected sale date of 08/28/2026 for the 50,000 shares of Eton Pharmaceuticals, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:41 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:41 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001182615
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Eton Pharmaceuticals, Inc.
SEC File Number	001-38738
Address of Issuer	21925 W. FIELD PARKWAY SUITE 235 DEER PARK ILLINOIS 60010-7278
Phone	(847) 787-7361
Name of Person for Whose Account the Securities are To Be Sold	MAIER PAUL V
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James and Associates inc. 880 Carillon Parkway St. Petersburg FL 33716	50000	2953530.00	28580000	08/28/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/28/2026	stock options	issuer			50000	08/28/2026	cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Paul W Maier
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)